Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04JCJ
|
|||
| Former ID |
DNC007800
|
|||
| Drug Name |
6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide
|
|||
| Synonyms |
CHEMBL235560; 6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide; SCHEMBL3702023; JKDWSAGAQLISRL-UHFFFAOYSA-N; BDBM50219927
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21N3O2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CNCCC2=CC=C(C=C2)OC3=CC=CC(=N3)C(=O)N
|
|||
| InChI |
1S/C21H21N3O2/c22-21(25)19-7-4-8-20(24-19)26-18-11-9-16(10-12-18)13-14-23-15-17-5-2-1-3-6-17/h1-12,23H,13-15H2,(H2,22,25)
|
|||
| InChIKey |
JKDWSAGAQLISRL-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor mu (MOP) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| Opioid Signalling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.